Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Lucid Diagnostics Inc. - Common Stock (NQ:LUCD)

1.180 -0.050 (-4.07%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Lucid Diagnostics Inc. - Common Stock

< Previous 1 2 Next >
October's 4 Best Penny Stocks: High-Risk, High-Reward Picks
Penny stocks are a risky but potentially rewarding opportunity for investors willing to take on their uncertainty; these stocks may stand out from the pack. 
Via MarketBeat
Topics Bankruptcy
PAVmed and Lucid Diagnostics Provide Strategic Business Update
From PAVmed Inc.
Via Business Wire
PAVmed and Lucid Diagnostics to Provide Strategic Business Update
From PAVmed Inc.
Via Business Wire
PAVmed Partners with Novosound on Ultrasound Imaging Technology
From PAVmed Inc.
Via Business Wire
Lucid Diagnostics Selected as Finalist for Medtech Company of the Year 2022 by Medical Device + Diagnostic Industry
From Lucid Diagnostics Inc.
Via Business Wire
PAVmed Digital Health Subsidiary Veris Health Launches Veris Cancer Care Platform
From PAVmed Inc.
Via Business Wire
Lucid Diagnostics Presents Real-World EsoCheck Data at the American Association for Cancer Research
From Lucid Diagnostics Inc.
Via Business Wire
PAVmed Provides Business Update and Third Quarter 2022 Financial Results
From PAVmed Inc.
Via Business Wire
Lucid Diagnostics Provides Business Update and Third Quarter 2022 Financial Results
From Lucid Diagnostics Inc.
Via Business Wire
Lucid Diagnostics to Participate in Canaccord Genuity’s MedTech, Diagnostics and Digital Health & Services Forum
From Lucid Diagnostics Inc.
Via Business Wire
Lucid Diagnostics Commences Production of EsoCheck Devices with High-Volume Manufacturer
From Lucid Diagnostics Inc.
Via Business Wire
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on November 14, 2022
From Lucid Diagnostics Inc.
Via Business Wire
Lucid Diagnostics Provides Business Update and Preliminary Second Quarter 2022 Financial Results
From Lucid Diagnostics Inc.
Via Business Wire
Lucid Diagnostics Launches Stage II Lucid Test Center Expansion in California, Texas, Florida, and Ohio
From Lucid Diagnostics Inc.
Via Business Wire
Newly Published American Gastroenterological Association Clinical Practice Update Supports Esophageal Precancer Screening Using Lucid Diagnostics’ EsoGuard® and EsoCheck® Technologies
From Lucid Diagnostics Inc.
Via Business Wire
Lucid Diagnostics’ Laboratory Executes Four New Participating Provider Agreements
From Lucid Diagnostics Inc.
Via Business Wire
Lucid Diagnostics to Hold a Business Update Conference Call on August 15, 2022
From Lucid Diagnostics Inc.
Via Business Wire
Lucid Diagnostics to Participate in the Canaccord 42nd Annual Growth Conference and the 7th Annual Needham Med Tech & Diagnostics 1x1 Conference
From Lucid Diagnostics Inc.
Via Business Wire
Lucid Diagnostics Provides Business Update and Preliminary First Quarter 2022 Financial Results
From Lucid Diagnostics Inc.
Via Business Wire
PAVmed and Lucid Diagnostics Chairman & CEO Lishan Aklog, M.D. Named Top 50 Healthcare Technology CEO
From PAVmed Inc.
Via Business Wire
Lucid Diagnostics to Hold a Business Update Conference Call on May 11, 2022
From Lucid Diagnostics Inc.
Via Business Wire
Lucid Diagnostics’ Laboratory Executes Participating Provider Agreement with MediNcrease Health Plans
From Lucid Diagnostics Inc.
Via Business Wire
PAVmed Provides Business Update and Preliminary Fourth Quarter and Full Year 2021 Financial Results
From PAVmed Inc.
Via Business Wire
Lucid Diagnostics Provides Updates on Newly Published Esophageal Precancer Clinical Guideline and Proposed Medicare Local Coverage Determination
From Lucid Diagnostics Inc.
Via Business Wire
Lucid Diagnostics Provides Business Update and Preliminary Fourth Quarter and Full Year 2021 Financial Results
From Lucid Diagnostics Inc.
Via Business Wire
Lucid Diagnostics to Participate in the Needham 21st Annual Healthcare Conference
From Lucid Diagnostics Inc.
Via Business Wire
PAVmed Subsidiary Lucid Diagnostics Announces Launch of VA EsoGuard® Study
From Lucid Diagnostics Inc.
Via Business Wire
PAVmed Subsidiary Lucid Diagnostics Launches Next Phase of Lucid Test Centers
From Lucid Diagnostics Inc.
Via Business Wire
PAVmed Appoints Shaun O’Neil as Chief Operating Officer
From PAVmed Inc.
Via Business Wire
Evernorth Executive and Healthcare Services Industry Leader Joan Harvey Named to PAVmed Board of Directors
From PAVmed Inc.
Via Business Wire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.